Le Lézard
Classified in: Health
Subject: TRI

Aphex BioCleanse Systems Celebrates Six Month Anniversary of Study Showing Ability of Company's Proprietary Sanitization Formula to Neutralize Candida Auris


PITTSFORD, N.Y., Sept. 29, 2020 /PRNewswire/ -- Aphex BioCleanse Systems, Inc. (OTC: SNST) ("Aphex" or "the Company"), a sanitization solutions company focused on the development and distribution of chemical-free, water-based sanitization and disinfection products, announced today that it is celebrating the six month anniversary of study results revealing that its proprietary Hy-IQ® Water formula effectively neutralizes Candida auris.

 

Challenge Microorganism
(AR-Bank #)

Replicate

Neutralization Phrase

Post Exposure Population (Log10)

Mean Log10 Post-Exposure Population

Results of Neutralization

Candida auris
(AR-Bank #0381)

1

Test Organism Viability
(Test C)

2.83

2.83

N/A

2

2.84

3

2.83

1

Neutralizer Toxicity (Test B)
Neutralizing Formulation:
Phosphate Buffered Saline with 0.1 (w/v) Sodium
Thiosulfate and 0.1% (v/v) Tween 80, pH 7.2
(PBS-T/ST)

2.84

2.86

Neutralizing
Non-Toxic1

2

2.84


3

2.89



1

Neutralizer Effectiveness (Test A)
Test Product: Gen 1 Special
Peracetic Acid
Lot #: X-106-18

2.83

2.84

Neutralizer
Effective1

2

2.83



3

2.85



1 = The mean log10 population was not more than 0.2 log10 lower than the Test Organism Viability

Aphex BioCleanse Systems proprietary Hy-IQ® Water formula shown to effectively neutralize Candida auris.

Candida auris is an emerging fungus in the United States that can cause severe infections in the bloodstream, wounds, ears and potentially other parts of the body. The Centers for Disease Control (CDC) has stated that it has concerns about Candida auris because it is often resistant to drugs commonly used to treat Candida infections. Candida auris is difficult to identify properly without specific technology and has been shown to cause outbreaks in healthcare settings.

"Candida auris is a powerful new strain of Candida that is emerging across the U.S. The CDC is actively dedicating resources in trying to kill the drug-resistant strain and research how to reduce infections and prevent it from spreading," said Aphex President and CEO David J. Weaver. "We are proud of the effectiveness of our Hy-IQ® Water technology as it easily neutralizes this particularly strong strain. We believe that our technology can be used both in the agriculture and healthcare sectors to kill Candida auris and help be part of the solution to getting the fungus under control."

Aphex submitted the Hy-IQ® Water to a laboratory In-Vitro Time-Kill study that was designed to test the kill rate on four different strains of Candida auris after 3 minutes, 5 minutes and 10 minutes. Results of the study reveal that Hy-IQ® Water was both non-toxic and effective in neutralizing the Candida auris strains.

To learn more about this and other quality and safety tests conducted on Hy-IQ® Water, please visit https://www.aphexus.com/test-data/.

About Aphex BioCleanse Systems, Inc.

Aphex BioCleanse Systems, Inc is the developer of the world's first proprietary non-alcohol, non-toxic, and hydrogen-based cleaning technology. The technology, called Hy-IQ® Water, has a unique method of action that uses hydrogen ions traveling nearly at the speed of light to breach the cell walls of exoskeleton germs. Preliminary research has proven that it is more effective in killing pathogens than alcohol-based solutions and the company is currently seeking to be the first FDA-approved hand sanitizer. Learn more about Aphex at www.aphexus.com.

FDA Statement

The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

[email protected] 
www.aphexus.com
Phone: 1-585-386-0990

Address:
Aphex BioCleanse Systems Inc.
15 Fishers Rd, #111
Pittsford, NY 14534

For media inquiries, please contact:
Kathryn Reinhardt
[email protected]
858-264-6600

 

SOURCE Aphex BioCleanse Systems Inc.


These press releases may also interest you

at 18:55
ZYUS Life Sciences Corporation ("ZYUS" or the "Company") is pleased to announce that Brent Zettl, President and CEO of ZYUS, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May...

at 18:42
George Weston Limited ("Weston" or the "Company") today announced that all of the nominee directors listed in its management proxy circular dated March 19, 2024, were elected as directors of the Company. The vote was conducted at the Company's...

at 18:41
Family Source Consultants, LLC, a leading provider of surrogacy, egg donation, and all third-party reproduction services, is excited to announce the grand opening of its new state-of-the-art office dedicated to enhancing the journeys of intended...

at 18:15
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024....

at 18:00
In recognition of Mother's Day on May 12th, Denny's Canada is delighted to announce that they have partnered with Women's Health Collective Canada (WHCC) to host a special fundraiser. From May 7th to 12th, in participating stores across Canada, $2...

at 17:41
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial...



News published on and distributed by: